Our biotherapies are indicated for the treatment of serious and rare conditions. These conditions include coagulation (bleeding) disorders, such as haemophilia and von Willebrand disease and immune deficiencies. Biotherapies are also used in the rapid reversal of warfarin and to prevent haemolytic disease of the foetus and newborn (HDFN).

Biotherapies differ from conventional chemical-derived pharmaceuticals in many ways. They are derived from human plasma or produced as their recombinant equivalents, instead of from chemicals. These expensive source materials comprise a much higher portion of the therapy’s cost than the chemicals used in pills and tablets. Biotherapies also undergo rigorous safety controls and inspections throughout every step of the year-long manufacturing process, from the collection of plasma to the final packaging of the finished product.

While plasma therapeutics treat small patient populations, traditional pharmaceuticals may treat millions of patients worldwide. As a result, economies of scale in the plasma protein industry are much narrower than in the traditional pharmaceutical industry. In fact, the cost of production for plasma-derived medical therapies is typically around 70% of the selling price compared to only about 19% for chemical-based pharmaceuticals.

Our products are produced at facilities in Bern, Switzerland; Marburg, Germany; Kankakee, Illinois; Wuhan, China and Broadmeadows, Australia; in accordance with international safety and quality standards. The company also operates CSL Plasma, one of the world’s largest plasma collection networks throughout the United States and Germany. CSL employs more than 20,000 people.

We are passionate about safety, quality and the customers we serve. Our extensive research, development and range of support services, demonstrates our ongoing commitment to all those who rely on our products.